Scenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officer

/in

Dr. Walker joins to lead Scenic’s transition into clinical development and shape its clinical strategy Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a key driver of multiple neurodegenerative disease Amsterdam, The Netherlands — 10 September 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose […]

Read more

Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34

/in

Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure Early biomarker signals are consistent with pathway modulation in the brain Teitur is planning to start a Phase II clinical trial of TT-P34 in PD in 2027 Aarhus, Denmark, September 10, […]

Read more

CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program

/in

€3.1 million financing led by new investor Clave Capital, with participation from existing investors Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout expected in mid-2027 Barcelona, Spain – 10 September 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address […]

Read more

Minoryx and Neuraxpharm complete enrolment in leriglitazone pivotal Phase 3 trial (CALYX) in adult patients with cerebral Adrenoleukodystrophy (cALD)

/in

Top-line results expected in early 2028; trial to support future label expansion in the EU and to enable NDA filing in the US Mataró, Barcelona, Spain, and Düsseldorf, Germany, 9 September 2026 – Minoryx Therapeutics and Neuraxpharm Group (Neuraxpharm), announce that the last patient has been enrolled in the global Phase 3 clinical trial (CALYX) […]

Read more
Vianautis

ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury

/in

Investment supports application of ViaNautis’ polyNaut® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrier Adds a new high-value CNS indication and provides further validation of polyNaut® as a versatile platform for precise, non-viral delivery of genetic medicines Cambridge, UK – 9 September 2026 – ViaNautis Bio (“ViaNautis”), the […]

Read more
© Optimum Strategic Communications.